Lockheed Martin vs. Northrop Grumman: Comparing Revenue Trends

Lockheed Martin continues to generate higher quarterly revenue than Northrop Grumman, with Q1 2026 revenue at $18.0B versus $9.9B and Q4 2025 at $20.3B versus $11.7B. The article highlights both companies' recent production-capacity expansions—Lockheed to quadruple interceptor output and Northrop to lift bomber production 25%—but the piece is mainly comparative and informational rather than event-driven. Two-year trailing revenue growth remains mid-single digits, at about 5.7% for Lockheed and 4.0% for Northrop.

Analysis

The incremental signal is not the absolute revenue level; it’s the divergence in operating leverage. LMT is showing the cleaner path to monetizing backlog into steady top-line expansion, while NOC’s flatter profile suggests more execution friction and a higher sensitivity to program mix. In defense, that usually matters more for multiples than headline growth because investors pay up for predictability when budgets are already spoken for.

Second-order, the capacity moves matter because they shift bargaining power with primes and subcontractors. If LMT can actually sustain a step-up in interceptor output, the constraint likely migrates downstream to propulsion, energetics, and precision components, which could tighten supplier margins and create localized shortages over the next 2-4 quarters. NOC’s bomber-capacity expansion is more vulnerable to a longer validation cycle; any launch/quality overhang makes near-term revenue visibility weaker and raises the odds of a stop-start production cadence.

The market may be underestimating how much the revenue gap itself can become a valuation catalyst. If LMT re-accelerates into another above-trend quarter while NOC remains flat, the spread should widen as investors pay for scale plus dividend durability; if NOC closes the gap, it would likely require meaningful program execution improvement, not just one quarter of backlog conversion. The asymmetry favors LMT on a 6-12 month horizon, but NOC can work tactically if management proves the capacity ramp is real and not simply a PR milestone.

The contrarian angle is that both names are already being treated as “safe compounders,” so the easy money from multiple expansion may be behind them. The real mispricing may be in whether investors are overreacting to quarter-to-quarter noise versus the multi-year demand runway from munitions, air defense, and space programs. That makes relative positioning more attractive than outright beta.

Key Decisions for Investors

• Long LMT / short NOC as a 6-12 month relative-value trade: target widening revenue and margin dispersion; cut if NOC shows two consecutive quarters of sequential acceleration.
• Add to LMT on any post-print weakness over the next 1-2 quarters: the setup is favorable if production capacity converts into backlog monetization; downside is mainly valuation compression, not demand.
• Use NOC only tactically via a 3-6 month call spread if management can demonstrate credible ramp execution; otherwise avoid owning it outright until production quality risk is resolved.
• Go long a defense supply-chain basket (precision components / propulsion / energetics names) on a 2-4 quarter horizon: capacity expansions at the primes should push bottlenecks and pricing power downstream.
• If LMT and NOC both rally on the same macro defense theme, fade the pair spread rather than the sector: the better risk/reward is in relative execution, not in betting against defense demand.